Recombinant human hyaluronidase facilitated subcutaneous immunoglobulin treatment in pediatric patients with primary immunodeficiencies: Long-term efficacy, safety and tolerability

Immunotherapy

Volumn 8, Issue 10, 2016, Pages 1175-1186

  Wasserman, Richard L ^a   Melamed, Isaac ^b   Kobrynski, Lisa ^c   Puck, Jennifer ^d   Gupta, Sudhir ^e   Doralt, Jennifer ^f   Sharkhawy, Marlies ^f   Engl, Werner ^f   Leibl, Heinz ^f   Gelmont, David ^g   Yel, Leman ^e,g  

^a Allergy/Immunology Research Center of North Texas   (United States)

^b IMMUNOe International Research Centers   (United States)

^c EMORY UNIVERSITY   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e UNIVERSITY OF CALIFORNIA   (United States)

^f Baxalta Innovations GmbH   (Austria)

^g SHIRE   (United States)

Author keywords

home infusion; hyaluronidase; immunoglobulin; IVIG; PIDD; primary immunodeficiency disease

Indexed keywords

HUMAN IMMUNOGLOBULIN; RECOMBINANT HYALURONIDASE; HISTONE ACETYLTRANSFERASE; HYALURONOGLUCOSAMINIDASE; IMMUNOGLOBULIN; MGEA5 PROTEIN, HUMAN; RECOMBINANT PROTEIN; TUMOR ANTIGEN;

ACUTE DISEASE; ADOLESCENT; AGE DISTRIBUTION; ARTICLE; BACTERIAL INFECTION; CHILD; CHILL; CLINICAL ARTICLE; CLINICAL ASSESSMENT; DISEASE SEVERITY; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; EPILEPTIC STATE; FATIGUE; FEMALE; FEVER; HEADACHE; HEART RATE; HUMAN; IMMUNE DEFICIENCY; INFECTION RATE; INFUSION RELATED REACTION; MALE; MULTICENTER STUDY; NAUSEA; PAIN; PERITONEUM ADHESION; PHASE 3 CLINICAL TRIAL; PNEUMONIA; PRIORITY JOURNAL; RESPIRATORY FAILURE; SYSTEMIC DISEASE; TONSIL DISEASE; TONSILLAR ENLARGEMENT; TREATMENT DURATION; TREATMENT PLANNING; VOMITING; CLINICAL TRIAL; GENETICS; IMMUNOLOGIC DEFICIENCY SYNDROMES; IMMUNOLOGY; PRESCHOOL CHILD; SUBCUTANEOUS DRUG ADMINISTRATION; TIME FACTOR; UNITED STATES;

ADOLESCENT; ANTIGENS, NEOPLASM; CHILD; CHILD, PRESCHOOL; FEMALE; HISTONE ACETYLTRANSFERASES; HUMANS; HYALURONOGLUCOSAMINIDASE; IMMUNOGLOBULINS; IMMUNOLOGIC DEFICIENCY SYNDROMES; INJECTIONS, SUBCUTANEOUS; MALE; RECOMBINANT PROTEINS; TIME FACTORS; UNITED STATES;

EID: 84986887441     PISSN: 1750743X     EISSN: 17507448     Source Type: Journal    
DOI: 10.2217/imt-2016-0066     Document Type: Article

References (46)

1. Picard C, Al-Herz W, Bousfiha A et al. Primary immunodeficiency diseases. An update on the classification from the International Union of Immunological Societies Expert Committee for Primary Immunodeficiency 2015. J. Clin. Immunol. 35(8), 696-726 (2015).
2. Sriaroon P, Ballow M. Immunoglobulin replacement therapy for primary immunodeficiency. Immunol. Allergy Clin. North Am. 35(4), 713-730 (2015).
3. Wasserman RL. Progress in gammaglobulin therapy for immunodeficiency: from subcutaneous to intravenous infusions and back again. J. Clin. Immunol. 32(6), 1153-1164 (2012).
4. Abolhassani H, Sadaghiani MS, Aghamohammadi A, Ochs HD, Rezaei N. Home-based subcutaneous immunoglobulin versus hospital-based intravenous immunoglobulin in treatment of primary antibody deficiencies: systematic review and meta analysis. J. Clin. Immunol. 32(6), 1180-1192 (2012).
5. Wasserman RL, Melamed I, Stein MR et al. Recombinant human hyaluronidase-facilitated subcutaneous infusion of human immunoglobulins for primary immunodeficiency. J. Allergy Clin. Immunol. 130(4), 951-957.e11 (2012).
6. Garcia-Lloret M, McGhee S, Chatila TA. Immunoglobulin replacement therapy in children. Immunol. Allergy Clin. North Am. 28(4), 833-849 (2008).
7. Ochs HD, Gupta S, Kiessling P, Nicolay U, Berger M, Subcutaneous IgG Study Group. Safety and efficacy of self-administered subcutaneous immunoglobulin in patients with primary immunodeficiency diseases. J. Clin. Immunol. 26(3), 265-273 (2006).
8. Misbah S, Sturzenegger MH, Borte M et al. Subcutaneous immunoglobulin. Opportunities and outlook. Clin. Exp. Immunol. 158(Suppl. 1), 51-59 (2009).
9. Ponsford M, Carne E, Kingdon C et al. Facilitated subcutaneous immunoglobulin (fSCIg) therapy - practical considerations. Clin. Exp. Immunol. 182(3), 302-313 (2015).
10. Frost GI. Recombinant human hyaluronidase (rHuPH20): an enabling platform for subcutaneous drug and fluid administration. Expert Opin. Drug Deliv. 4(4), 427-440 (2007).
11. Thomas JR, Yocum RC, Haller MF, von Gunten CF. Assessing the role of human recombinant hyaluronidase in gravity-driven subcutaneous hydration: The INFUSE-LR Study. J. Palliat. Med. 10(6), 1312-1320 (2007).
12. Harb G, Lebel F, Battikha J, Thackara JW. Safety and pharmacokinetics of subcutaneous ceftriaxone administered with or without recombinant human hyaluronidase (rHuPH20) versus intravenous ceftriaxone administration in adult volunteers. Curr. Med. Res. Opin. 26(2), 279-288 (2010).
13. Allen CH, Etzwiler LS, Miller MK et al. Recombinant human hyaluronidase-enabled subcutaneous pediatric rehydration. Pediatrics 124(5), e858-e867 (2009).
14. Spandorfer PR, Mace SE, Okada PJ et al. A randomized clinical trial of recombinant human hyaluronidasefacilitated subcutaneous versus intravenous rehydration in mild to moderately dehydrated children in the emergency department. Clin. Ther. 34(11), 2232-2245 (2012).
15. Wasserman RL, Melamed I, Stein MR et al. Long-term tolerability, safety and efficacy of recombinant human hyaluronidase-facilitated subcutaneous infusion of human immunoglobulin for primary immunodeficiency. J. Clin. Immunol. 36(6), 571-582 (2016).
16. Wasserman RL. Subcutaneous immunoglobulin: facilitated infusion and advances in administration. Clin. Exp. Immunol. 178(Suppl. 1), 75-77 (2014).
17. Geha RS, Notarangelo LD, Casanova JL et al. Primary immunodeficiency diseases - an update from the International Union of Immunological Societies Primary Immunodeficiency Diseases Classification Committee. J. Allergy Clin. Immunol. 120(4), 776-794 (2007).
18. Rosengren S, Dychter SS, Printz MA et al. Clinical immunogenicity of rHuPH20, a hyaluronidase enabling subcutaneous drug administration. AAPS J. 17(5), 1144-1156 (2015).
19. Orange JS, Grossman WJ, Navickis RJ, Wilkes MM. Impact of trough IgG on pneumonia incidence in primary immunodeficiency: a meta-analysis of clinical studies. Clin. Immunol. 137(1), 21-30 (2010).
20. Quinti I, Soresina A, Guerra A et al. Effectiveness of immunoglobulin replacement therapy on clinical outcome in patients with primary antibody deficiencies-results from a multicenter prospective cohort study. J. Clin. Immunol. 31(3), 315-322 (2011).
21. Baxter Bioscience. Briefing Book, Blood Products Advisory Committee Meeting, July 31, 2014, HyQvia Immune Globulin Infusion 10% (Human) with Recombinant Human Hyaluronidase. 204 (2014). www.fda.gov
22. Wasserman RL, Melamed I, Kobrynski L et al. Efficacy, safety, and pharmacokinetics of a 10% liquid immune globulin preparation (GAMMAGARD LIQUID, 10%) administered subcutaneously in subjects with primary immunodeficiency disease. J. Clin. Immunol. 31(3), 323-331 (2011).
23. Gardulf A, Björvell H, Gustafson R, Hammarström L, Smith CI. Safety of rapid subcutaneous gammaglobulin infusions in patients with primary antibody deficiency. Immunodeficiency 4(1-4), 81-84 (1993).
24. Hagan JB, Fasano MB, Spector S et al. Efficacy and safety of a new 20% immunoglobulin preparation for subcutaneous administration, IgPro20, in patients with primary immunodeficiency. J. Clin. Immunol. 30(5), 734-745 (2010).
25. Frost GI, Stern R. A microtiter-based assay for hyaluronidase activity not requiring specialized reagents. Anal. Biochem. 251(2), 263-269 (1997).
26. Baxalta Incorporated. Annex I Summary of product characteristics HyQvia 100 mg/ml solution for infusion for subcutaneous use. 43 (2015). www.ema.europa.eu
27. Patel NC, Gallagher JL, Ochs HD et al. Subcutaneous immunoglobulin replacement therapy with Hizentra® is safe and effective in children less than 5 years of age. J. Clin. Immunol. 35(6), 558-565 (2015).
28. Bayer Corporation. Package Insert, Immune Globulin Intravenous (Human) Gamunex. 16- (2003). www.baxter.ca
29. Wasserman RL, Melamed I et al., Nelson RP Jr Pharmacokinetics of subcutaneous IgPro20 in patients with primary immunodeficiency. Clin. Pharmacokinet. 50(6), 405-414 (2011).
30. Bonagura VR, Marchlewski R, Cox A, Rosenthal DW. Biologic IgG level in primary immunodeficiency disease: the IgG level that protects against recurrent infection. J. Allergy Clin. Immunol. 122(1), 210-212 (2008).
31. Stiehm ER. Human intravenous immunoglobulin in primary and secondary antibody deficiencies. Pediatr. Infect. Dis. J. 16(6), 696-707 (1997).
32. Borte M, Pac M, Serban M et al. Efficacy and safety of Hizentra® , a new 20% immunoglobulin preparation for subcutaneous administration, in pediatric patients with primary immunodeficiency. J. Clin. Immunol. 31(5), 752-761 (2011).
33. Church J, Borte M, Taki H et al. Efficacy and safety of Privigen in children and adolescents with primary immunodeficiency. Pediatr. Asthma Allergy Immunol. 22(2), 53-61 (2009).
34. Gardulf A, Nicolay U, Asensio O et al. Rapid subcutaneous IgG replacement therapy is effective and safe in children and adults with primary immunodeficiencies - a prospective multi-national study. J. Clin. Immunol. 26(2), 177-185 (2006).
35. Wasserman RL, Church JA, Peter HH et al. Pharmacokinetics of a new 10% intravenous immunoglobulin in patients receiving replacement therapy for primary immunodeficiency. Eur. J. Pharm. Sci. 37(3-4), 272-278 (2009).
36. Wasserman RL, Irani AM, Tracy J et al. Pharmacokinetics and safety of subcutaneous immune globulin (human), 10% caprylate/chromatography purified in patients with primary immunodeficiency disease. Clin. Exp. Immunol. 161(3), 518-526 (2010).
37. Stein MR, Nelson RP, Church JA et al. Safety and efficacy of Privigen® , a novel 10% liquid immunoglobulin preparation for intravenous use, in patients with primary immunodeficiencies. J. Clin. Immunol. 29(1), 137-144 (2009).
38. U. S. Department of Health and Human Services, Food and Drug Administration, and Center for Biologics Evaluation and Research. Guidance for industry. Safety, efficacy, and pharmacokinetic studies to support marketing of immune globulin intravenous (human) as replacement therapy for primary humoral immunodeficiency. 17- (2008). www.fda.gov
39. Jolles S, Bernatowska E, De Gracia J et al. Efficacy and safety of Hizentra® in patients with primary immunodeficiency after a dose-equivalent switch from intravenous or subcutaneous replacement therapy. Clin. Immunol. 141(1), 90-102 (2011).
40. Wasserman RL, Church JA, Stein M et al. Safety, efficacy and pharmacokinetics of a new 10% liquid intravenous immunoglobulin (IVIG) in patients with primary immunodeficiency. J. Clin. Immunol. 32(4), 6637-6669 (2012).
41. Gardulf A, Nicolay U, Asensio O et al. Children and adults with primary antibody deficiencies gain quality of life by subcutaneous IgG self-infusions at home. J. Allergy Clin. Immunol. 114(4), 936-942 (2004).
42. Craske MG. Fear and anxiety in children and adolescents. Bull. Menninger Clin. 61(2 Suppl. A), A4-A36 (1997).
43. Kleinknecht RA. Acquisition of blood, injury, and needle fears and phobias. Behav. Res. Ther. 32(8), 817-823 (1994).
44. Cemeroglu AP, Can A, Davis AT et al. Fear of needles in children with type 1 diabetes mellitus on multiple daily injections and continuous subcutaneous insulin infusion. Endocr. Pract. 21(1), 46-53 (2015).
45. Larsen P, Eldridge D, Brinkley J et al. Pediatric peripheral intravenous access. Does nursing experience and competence really make a difference? J. Infus. Nurs. 33(4), 226-235 (2010).
46. Claxton AJ, Cramer J, Pierce C. A systematic review of the associations between dose regimens and medication compliance. Clin. Ther. 23(8), 1296-1310 (2001).